Roivant Sciences reports on Monday 9 November, before the market opens. The analysts' average EPS estimate for the quarter is −$0.45, and the report will test whether the company's four-quarter beat streak continues while trailing-twelve-month revenue has fallen 67.6% to $7.5 million.
Source: reported quarterly EPS and aggregated third-party estimates. Historical surprises are context, not a forecast.
View chart data
| Period | Reported EPS | Analysts' estimate |
|---|---|---|
| Sep '25 | −$0.28 | −$0.30 |
| Dec '25 | −$0.24 | −$0.31 |
| Mar '26 | −$0.32 | −$0.35 |
| Jun '26 | −$0.34 | −$0.36 |
What analysts expect from Roivant Sciences
The analysts' average EPS estimate for the quarter is −$0.45, in a range from −$0.59 to −$0.35. The average revenue estimate for the quarter is $3.7 million. For the full year, the analysts' average EPS estimate is −$1.58, which would be down 46.7% on last year. The estimate is based on 11 analysts, of whom 11 carry a positive recommendation, 2 are neutral and none are negative.
Earnings surprise model
Our model estimates EPS could land above the analysts' average estimate by 4.7%. The model's estimated chance of an EPS beat is 75.0%, based on the last 4 quarters. The model shrinks the median recent surprise toward zero and uses a neutral prior for beat frequency; with only four quarters in the sample, this is a reference estimate, not company guidance.
Roivant Sciences' record against estimates
The company reported EPS above the analysts' average estimate in 4 of the last 4 quarters. Last quarter, EPS of −$0.34 compared with an estimate of −$0.36, above it by 4.9%. The model's beat probability draws on the same four-quarter window.
The decline in sales is easing
Revenue over the trailing twelve months was $7.5 million, down 67.6% on the year before. The growth rate was up 4.0 percentage points on the rate a quarter earlier, so the decline is narrowing. Against that revenue base, the trailing operating margin stands at −7914.8%, down 2810.0 percentage points from a year earlier. The trailing net margin is −3535.0%, and the company made a net loss of $266.3 million over the twelve months.
Cash flow deepens the picture. Operating cash flow over the twelve months was −$816.5 million. Capital spending was $4.6 million, or 61.0% of revenue. Free cash flow, operating cash flow less capital spending, was −$821.1 million. As a share of revenue, that is a free-cash-flow margin of −10901.0%, down 7205.1 percentage points from a year earlier. The average diluted share count rose 0.6% over the year.
Against its own history, today's free-cash-flow margin is below every one of the company's past quarterly readings, which have ranged from −9183.5% to −1064.5%. Today's operating margin of −7914.8% is higher than 5% of past readings, which range from −9130.5% to 12712.6%. Today's twelve-month revenue growth rate of −67.6% is higher than 6% of past readings, which range from −71.6% to 132.3%.
Questions this report will answer
The report will answer whether the pick-up in revenue growth continues, whether results land above or below the analysts' expectations set out above, and whether margins hold at the trailing levels reported here.
